Point72 Hong Kong LTD Bio Atla, Inc. Transaction History

Point72 Hong Kong LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$2.94 - $11.87 $1,237 - $4,997	421 New	421 $3,000
Q2 2022 Aug 15, 2022	SELL	$2.13 - $5.38 $18,234 - $46,058	-8,561 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$4.38 - $18.78 $33,524 - $143,742	7,654 Added 843.88%	8,561 $43,000
Q4 2021 Feb 14, 2022	SELL	$19.0 - $30.95 $40,793 - $66,449	-2,147 Reduced 70.3%	907 $18,000
Q3 2021 Nov 15, 2021	BUY	$29.44 - $43.74 $89,909 - $133,581	3,054 New	3,054 $90,000

17.3M

500

33.5K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $62.4M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.